Login
BridgeBio Pharma, Inc. logo

BridgeBio Pharma, Inc.

bridgebio.com

What Do They Do?

Sells medicines for genetic diseases and develops additional drug candidates for patients with genetic conditions.

How Do They Make Money?

BridgeBio sells medicines to specialty pharmacies and distributors, with revenue tied to their receipt of the product. It also earns license and service revenue and royalties from partners commercializing licensed products.

FY2025 revenue by product or service revenue
SegmentShareRevenue
Net product revenue
Sold outright

72%
FY2022: 2.0%
License and services revenue
26%
FY2022: 98%
Royalty revenue
Licensed
2.3%

Who Are Their Customers?

Specialty pharmacies and specialty distributors buy the company’s medicines. Outside the United States, Bayer and Alexion commercialize Beyonttra under license; BridgeBio also commercializes it directly in certain international markets.

Do Revenues Turn Into Profits?

No. It lost $724.9M in FY2025.

Operating income, FY2025
−104% of revenue
▲ +12% (Loss) vs FY2024 (−$593M, −267%)
Net income, FY2025
−144% of revenue
▼ −35% (Loss) vs FY2024 (−$535.8M, −241%)
Free cash flow, FY2025
−89% of revenue
▲ +14% (Loss) vs FY2024 (−$521.7M, −235%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +193%
vs $120.7M in Q3 FY2025
Net income
▲ +69% (Loss)
vs −$182.7M in Q3 FY2025
Net product revenue share of revenue vs 89.6% in Q3 FY2025
  • Aug 31, 2026 Agrees with U.S. government to expand Medicaid access to Attruby The voluntary agreement expands state Medicaid access to Attruby; BridgeBio says its pricing commitment excludes medicines approved exclusively for orphan indications.

Growing. Revenue grew 7.2x in 4 years, from $69.7M in FY2021 to $502.1M in FY2025, about 64% a year.

Acquired a marketed product The earlier report described acoramidis as under clinical development; the latest says BridgeBio markets it in the United States as Attruby after approval.

Oncology moved outside the core portfolio The earlier report included a KRAS inhibitor portfolio for cancers; the latest describes BridgeBio Oncology Therapeutics as a separate spun-out company in which BridgeBio retains an equity interest.

Revenue over time
Net product revenue License and services revenue Royalty revenue
$1B$500M$0

Who Do They Compete With?

Competes with Pfizer, Alnylam Pharmaceuticals, Ascendis Pharma, Tyra Biosciences, Ribomic, and BioMarin Pharmaceutical

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support